Biostage (OTCMKTS:BSTG – Get Free Report) and INVO Fertility (NASDAQ:IVF – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.
Profitability
This table compares Biostage and INVO Fertility’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biostage | N/A | N/A | -174.43% |
| INVO Fertility | -417.02% | N/A | -92.42% |
Earnings and Valuation
This table compares Biostage and INVO Fertility”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biostage | N/A | N/A | -$6.07 million | ($0.58) | -7.67 |
| INVO Fertility | $6.53 million | 0.54 | -$9.10 million | ($3,151.46) | 0.00 |
Biostage has higher earnings, but lower revenue than INVO Fertility. Biostage is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Biostage and INVO Fertility, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biostage | 0 | 0 | 1 | 0 | 3.00 |
| INVO Fertility | 1 | 0 | 0 | 1 | 2.50 |
INVO Fertility has a consensus target price of $20.00, indicating a potential upside of 821.66%. Given INVO Fertility’s higher possible upside, analysts clearly believe INVO Fertility is more favorable than Biostage.
Risk and Volatility
Biostage has a beta of -1.02, suggesting that its share price is 202% less volatile than the S&P 500. Comparatively, INVO Fertility has a beta of 2.64, suggesting that its share price is 164% more volatile than the S&P 500.
Institutional and Insider Ownership
12.0% of INVO Fertility shares are held by institutional investors. 15.3% of Biostage shares are held by company insiders. Comparatively, 0.7% of INVO Fertility shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
INVO Fertility beats Biostage on 7 of the 13 factors compared between the two stocks.
About Biostage
Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.
About INVO Fertility
INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.
Receive News & Ratings for Biostage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage and related companies with MarketBeat.com's FREE daily email newsletter.
